ArticleOphthalmology science2026
Integrative Network Pharmacology Analysis of Gut Microbial Metabolite-Mediated Gut-Eye Axis Regulation in Major Blinding Retinal Diseases.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically investigate the shared and disease-specific mechanisms by which gut microbial metabolites may regulate age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) through a network pharmacology framework. Design: Bioinformatics-based network pharmacology study. Subjects: Publicly available gut microbial metabolite, metabolite-target, and disease-associated gene data sets related to AMD, DR, and RVO were analyzed. Methods: Gut microbial metabolites were retrieved from gutMGene, and potential human targets were predicted using the Similarity Ensemble Approach and SwissTargetPrediction. Disease-associated genes were collected from GeneCards, Online Mendelian Inheritance in Man, and the Comparative Toxicogenomics Database. Intersection genes were analyzed using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Protein-protein interaction networks were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins database, and candidate hub targets were prioritized in Cytoscape. Drug-likeness and toxicity profiles of key metabolites were evaluated using SwissADME and ADMETlab 3.0. An integrated microbiota-substrate-metabolite-target (M-S-M-T) network was constructed to characterize gut-eye axis regulation. Main Outcome Measures: Intersection genes, enriched biological functions and pathways, high-centrality candidate hub targets, predicted drug-likeness and toxicity profiles of metabolites, and M-S-M-T regulatory relationships. Results: A total of 226 gut microbial metabolites and 1518 predicted host targets were identified. Intersection analysis revealed 47, 44, and 40 metabolite-related genes associated with AMD, DR, and RVO, respectively, including 38 genes shared across all 3 diseases. Enrichment analyses showed convergent involvement of microbial signal sensing, inflammatory regulation, oxidative stress, apoptosis, and vascular homeostasis. Nuclear factor kappa B, mitogen-activated protein kinase, phosphatidylinositol 3-kinase-protein kinase B, tumor necrosis factor, VEGF, Toll-like receptor, and nucleotide-binding oligomerization domain-like receptor pathways formed a shared inflammatory-oxidative-vascular signaling module. Protein-protein interaction analysis identified interleukin 6, tumor necrosis factor, protein kinase B alpha, and tumor protein p53 as recurrent high-centrality candidate hub targets. Key metabolites, including indole-3-propionic acid, tryptamine, phenylalanine, and indole-3-lactic acid, showed favorable predicted drug-likeness and safety profiles. Conclusions: Gut microbial metabolites may contribute to AMD, DR, and RVO through shared inflammatory, oxidative stress, and vascular signaling networks. These findings provide a systems-level framework for gut-eye axis regulation and support further experimental validation of microbiota-based systemic intervention strategies. Financial Disclosures: The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.